San Francisco

Nationwide Testosterone Lawyers For Heart Attack and Stroke Victims


Nationwide Testosterone Lawsuit Attorney Network


Get A  Testosterone Lawsuit  Lawyer  Handling Testosterone Heart Attack and  Stroke Lawsuits

If you or a loved one suffered from a heart attack or stroke while using AndroGel you may be entitled to damages. We provide free no-obligation Atlanta testosterone lawsuit case review. We do not charge attorney fees unless you receive compensation and you are under no obligation after your initial consultation.

Testosterone Therapy May Raise Heart Attack Risks

Researchers say risk of heart attack doubles after treatment starts for men under 65 with heart problems and all men over 65.

Nationwide  AndroGel  Lawsuit Attorneys
Testosterone Stroke and Heart Attack

AndroGel® (testosterone gel)  is a daily testosterone replacement therapy  that can help bring T levels back to normal with daily use.

FDA Is  Investigating Potential  Heart Attacks And  Strokes From Testosterone Products

On Jan. 31, 2014, the  FDA announced  it would be investigating the risk of heart attacks, strokes and possible  deaths in men using  testosterone products. The FDA made this announcement after reviewing the study conducted at the National Cancer Institute, as well as the study published in JAMA. The FDA recommended the health care practitioners should  consider the benefits of testosterone treatment and potential the  risks.

If you or a loved one has had a stroke or heart attack after using testosterone therapy call now and get connected to one of our experienced testerone lawyers

 

 

 

 

 

GranuFlo Recall, Dialysis Medication Lawsuits, Heart Attack From Dialysis Medication Lawyers

GranuFlo is used in Dialysis treatment. it has been recalled due to sudden heart attacks and deaths. Heart attack from dialysis medication lawyers are filing lawsuits for deaths from dialysis medications.

Definitions and Kindney Disease Overview

Chronic kidney disease (CKD): any condition that causes reduced kidney function over a period of time. CKD is present when a patient’s glomerular filtration rate remains below 60 milliliters per minute for more than 3 months or when a patient’s urine albumin-to-creatinine ratio is over 30 milligrams (mg) of albumin for each gram (g) of creatinine (30 mg/g).

End-stage renal disease (ESRD): total and permanent kidney failure. When the kidneys fail, the body retains fl uid. Harmful wastes build up. A person with ESRD needs treatment to replace the work of the failed kidneys.

Acute kidney injury (AKI): sudden, temporary, and sometimes fatal loss of kidney function

incidence: the number of new cases of a disease in a given time period

prevalence: the number of existing cases of a disease at a given point in time


Chronic Kidney Disease, Dialysis and GranuFlo. GranuFlo is a Threat to Seniors

  •     The incidence of CKD is increasing most rapidly in people ages 65 and older.
  •     The incidence of recognized CKD in people ages 65 and older more than doubled between 2000 and 2008.
  •     The incidence of recognized CKD among 20- to 64-year-olds is less than 0.5 percent.

CKD Prevalence, GranuFlo Threat in 60 and Over Population

    The prevalence of CKD is growing most rapidly in people ages 60 and older.
    Between the 1988–1994 National Health and Nutrition Examination Survey (NHANES) study and the 2003–2006 NHANES study, the prevalence of CKD in people ages 60 and older jumped from 18.8 to 24.5 percent.
    During that same period, the prevalence of CKD in people between the ages of 20 and 39 stayed consistently below 0.5 percent.

Dialysis Statistics By State

  • Alabama: 7,334
  • Alaska: 350
  • Arizona: 6,747
  • Arkansas:2,905
  • California: 45,047
  • Colorado: 3,360
  • Connecticut: 3,497
  • DC:1,809
  • Delaware: 1,170
  • Florida: 20,365
  • Georgia: 14,086
  • Hawaii: 2,449
  • Idaho: 916
  • Illinois: 15,268
  • Indiana: 6,539
  • Iowa: 2,296
  • Kansas: 2,384
  • Kentucky: 4,262
  • Louisiana: 7,287
  • Maine: 975
  • Maryland: 7,823
  • Massachusetts: 5,123
  • Michigan:12,293
  • Minnesota: 3,697
  • Mississippi:5,456
  • Missouri:6,467
  • Montana: 627
  • Nebraska:1,473
  • Nevada: 2,294
  • New Hampshire: 690
  • New Jersey: 10,580
  • New Mexico: 2,451
  • New York: 23,612
  • North Carolina: 12,895
  • North Dakota: 501
  • Ohio: 13,761
  • Oklahoma:3,793
  • Oregon: 2,703
  • Pennsylvania: 14,201
  • Puerto Rico:4,032
  • Rhode Island: 838
  • South Carolina: 7,199
  • South Dakota: 689
  • Tennessee: 7,482
  • Texas: 32,383
  • Utah: 1,303
  • Vermont: 380
  • Virginia: 9,332
  • Washington: 5,026
  • West Virginia: 1,794
  • Wisconsin: 4,899
  • Wyoming:248


The high incidence of Dialysis treatment in Florida is due to the numbers of aging population. Our Florida Seniors are at risk for sudden heart attack form the dialysis medication GranuFlo and Naturalyte.

Fresenius labs has used GranuFlo and Naturalyte in Dialysis  Treatments. Fresnius knew of the dangers and still used the medication. As a result many of our seniors have suffered cardiac arrest and heart problems

Fresenius  Claima  To Be Patient-Centered Care for Chronic Kidney Disease

Fresenius Medical Care North America is a major provider of kidney dialysis services and renal care products. We provide products, dialysis care services, education and support for Chronic Kidney Disease (CKD), including treatment options for later stage CKD.

Our dialysis care services include hemodialysis, peritoneal dialysis, education tools and transplant support services, in-center, at home, or in a hospital, to fit our patients' needs. We manufacture and distribute a variety of dialysis products and equipment, including dialysis machines, dialyzers and other dialysis-related supplies.

FDA Issues Class 1 Recall of GranuFlo

In late March of 2012, the FDA became aware of the apparent link between GranuFlo and cardiac arrest, according to the New York Times. In response to information about this threat to dialysis patients, which GranuFlo producer Fresenius had not made public, the FDA issued a Safety Communication warning about the dangers of alkali dosing errors for products like GranuFlo and NaturaLyte in hemodialysis patients.

In June, the FDA then issued a Class 1 recall of GranuFlo. This is the most serious class of recall, issued when the FDA deems there to be "a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death." The FDA described the reason for the recall thus:

    The manufacturer is cautioning clinicians to be aware of the concentration of acetate or sodium diacetate (acetic acid plus acetate) contained in Fresenius' Naturalyte Liquid and Granuflo Dry Acid Concentrate. Inappropriate prescription of these products can lead to a high serum bicarbonate level in patients undergoing hemodialysis. This may contribute to metabolic alkalosis, which is a significant risk factor associated with low blood pressure, hypokalemia, hypoxemia, hypercapnia and cardiac arrhythmia, which, if not appropriately treated, may culminate in cardiopulmonary arrest. This product may cause serious adverse health consequences, including death.

GranuFlo Lawsuits Mounting Up. Protect Our Seniors, File Your GranuFlo Lawsuit Today

GranuFlo and NaturaLyte lawsuits are being filed in courts around the country, after hundreds of patients suffered cardiac arrest, sudden cardiac death. Pur seniors are in danger.  Serious heart problems have been reported following  the use of the drugs during dialysis treatments.   While Fresenius Medical, the manufacturer of GranuFlo and NaturaLyte, learned of the risks associated with the dialysis drugs in 2011, a GranuFlo and NaturaLyte recall was not announced until months later. GranuFlo and NaturaLyte lawsuits are now being filed on behalf of our seniors  who are victims of  serious heart side effects within 48 hours of a dialysis treatment with  GranuFlo and Naturalyte. Problems include: sudden cardiac death, cardiopulmonary arrest, heart attack and the development of heart problems.
 

File Your GranuFlo Lawsuit and Protect Your Loved Ones. Get Justice form Manufacturers who value profits over harm to people. If you, a loved one or someone you are a caregiver for has been injured by a dialysis medication call the GranuFlo Lawyer Helpline of Free Legal Shiels today.


 

Dialysis Injury Help Center, GranuFlo Naturalyte Helpline

Lawyers for GranuFlo and Naturalyte are filing lawsuits for dialysis injury from Granuflo and Naturalyte. Fresenius Medical Care’s dialysis product GranuFlo is  a medication  that  dialysis centers   use to treat acute and chronic kidney failure.
 

Your kidneys clean the blood of waste  products  and help maintain the body’s pH level. When they fail, the body’s pH level become more acidic than is should be.  Kidney failure is treated with chemicals that help the body convert ph level. These substances convert  into the alkaline substance bicarbonate, which neutralizes some of the acid buildup in the blood stream.
GranuFlo  and Naturalyte have had issues with this conversion and have shown instances of immediate  heart attacks as a side effect. GranuFlo contains more bicarbonate than other dialysates.

The June 2012 New York Times article describes Fresenius’s knowledge of these risks  of granuFlo and Naturalyte and the product’s high bicarbonate level. According to the article, Fresenius sent a memo to its clinics warning that the higher bicarbonate levels in GranuFlo had caused 941 heart attacks in the company’s own clinics in 2010, leading the company’s researchers to estimate that GranuFlo increases a patient’s risk of heart attack by six times. Fresenius did not send the memo to GranuFlo-using clinics that the company didn’t own, however, until March 29, 2012, when the FDA consequently began investigating Fresenius for possible violations of federal regulations, the Times reports.

Currently GranuFlo and Naturalyte lawyers are accepting claims against Fresenius for immediate hear attack  form their GranuFlo and Naturalyte products. A number of dialysis patients may have already been injured by GranuFlo. If  GranuFlo diaysis medication caused a sudden heart attack or cardiac arrest, hemodialysis cardiac arrest or cardiopulmonary arrest, stroke, or arrhythmia speak to a GranuFlo lawyer now by calling the GranuFlo legal team of free legal Shield. We seek justice for seniors.

Mesothelioma Lawsuits, Mesothelioma Lawyers, Asbestos, Lung Cancer

Mesothelioma is a fatal lung cancer caused by exposure to asbestos. Certain work environments are more prone to causing mesothelioma.

  •     Shipyard Workers
  •     Construction Workers
  •     Power Plant Workers
  •     Chemical Plant Workers
  •     Industrial Workers
  •     Insulators
  •     Boiler Workers
  •     Auto Mechanics

Types of mesothelioma

  •     Pleural mesotheliomas start in the chest.
  •     Peritoneal mesotheliomas begin in the abdomen.

 

 Symptoms of Mesothelioma

  •     Shortness of breath and
  •     A heavy feeling in the chest area.
  •     Pain under the rib cage.
  •     Pain or swelling in the abdomen.
  •     Lumps in the abdomen.
  •     Weight loss for no known reason.

Mesothelioma Comes from Inhaling Asbestos For Long Periods Of Time

When a person breathes in the small asbestos fibers, they remain in the lungs and cause scar tissue to form on the the tiny air sacs where oxygen and carbon dioxide are exchanged. The amount of oxygen that is available to the body is reduced through asbestos exposure and worsened through repeated inhalations for long periods of time.

Notable asbestos verdicts in the United States include:
Mississippi

– In May 2011, the current largest plaintiff's asbestos verdict was awarded to a former oil refinery worker. Union Carbine and Chevron Phillips Chemical were instructed to pay the man $322 million.
San Francisco, California

– Alfred Todak, a former Navy electrician, was awarded $22.7 million, and his was wife was awarded $11 for loss of consortium.
Madison County, Illinois

– Madison County's asbestos verdicts have typically favored the plaintiff, including the 2000 Hutchinson v. Shell Oil Company case in which a man was awarded a total of $34.1 million.

Incidence of Mesothelioma

State/Region  Incidence per 100,000
New Jersey  1.52
Seattle-Puget Sound  1.44
Louisiana  1.37
Connecticut  1.08
Greater California  1.06
Utah  1.02
New Mexico  0.99
Detroit  0.89
Kentucky  0.85
Iowa  0.80
Georgia  0.70

The six states with the highest mesothelioma death rates include: Maine, Wyoming, West Virginia, Pennsylvania, New Jersey and Washington

Mesothelioma Lawyers

If you or a loved one has been diagnosed with mesothelioma or asbestos related cancer call our mesothelioma helpline today. We will connect you with an experienced mesothelioma, mass tort lawyer. Mesothelioma lawsuits are mass torts and must be handled by an experienced mass tort lawyer.

  

 

 

Januvia, Byetta Risks of Pancreatic Cancer, Lawyers Looking At Lawsuits

New Information on Byetta and Januvia is gaining interest by lawyers for Pancreatic and Thyroid Cancer. Type II Diabetics are potential victims of cancer from these Diabetic drugs.

Popular diabetes drugs may raise pancreatic cancer risk, study suggests
By Steven Reinberg, HealthDay
Updated 9/23/2011 6:15 PM

People with type 2 diabetes taking the drugs Januvia or Byetta might have an increased risk of developing pancreatitis and pancreatic cancer, a preliminary study suggests.
Sponsored Links

The study also found that Byetta (exenatide) may raise the risk of thyroid cancer.

Although the links aren't conclusive, they merit further investigation, the researchers noted.

"We have raised concern that there may be a link, but we haven't confirmed it," said lead researcher Dr. Peter Butler, director of the Larry L. Hillblom Islet Research Center at the University of California, Los Angeles. "We need to do more work to figure out whether this is real or not."

Both drugs help control blood sugar levels by encouraging production of a hormone called glucagon-like peptide 1 (GLP-1).

Januvia (sitagliptin) and Byetta, an injectable drug, are a new way of treating type 2 diabetes, and they potentially have advantages over older medications, Butler said. But, because these drugs are new, they're "the ones we know least about," he said. "When new drugs come out, the long-term side effects of these drugs are not well understood."

For the study, recently published in the journal Gastroenterology, Butler's team used 2004-2009 information in the U.S. Food and Drug Administration's database on adverse events, which are reported by doctors whose patients use these drugs.

When compared to other treatments, the researchers found a sixfold increase of reported cases of pancreatitis (inflammation of the pancreas) linked to patients taking Januvia or Byetta; a 2.9-fold increase in reported cases of pancreatic cancer among those taking Byetta and a 2.7-fold increase of reported pancreatic cancers among Januvia users.

In addition, they also noted an increase in reported cases of thyroid cancer with Byetta.

This latest study builds on earlier research, published in a 2009 issue of Diabetes, which found an increase in pancreatitis in rats whose GLP-1 levels were raised, the researchers said.

Butler is quick to point out that these increases in pancreatic cancer risk, while statistically significant, are not specifically related to patients, but rather to an increase in doctors reporting these cases to the FDA.

"It is important to avoid alarmism and have people stop medicines that they may be benefitting from when the risk is not yet defined," he stressed.

"If the drug and you are working well together, I wouldn't say there is any reason to stop the drug, based on the evidence we have right now," he said. "But if you have any concern you should talk to your doctor about it."

Being overweight is an important risk for both pancreatic cancer and type 2 diabetes, Butler noted. So the first advice to overweight patients with type 2 diabetes is to lose weight. "By doing that, you reduce the risk of pancreatic cancer," he said.

In addition, the first medication used to control blood sugar in type 2 diabetics is metformin, which by itself may reduce the risk for pancreatic cancer, Butler said. Metformin is an older drug with a well-known safety profile, he noted.

Dr. Mary Ann Banerji, director of the Diabetes Treatment Center at SUNY Health Science Center Brooklyn in New York City, said that "this is not perfect data."

However, Banerji does not prescribe these drugs for patients who have had a history of pancreatitis or a family history of thyroid cancer. There are alternatives such as metformin and insulin, as well as Avandia and Actos, she said, but studies have turned up an increased risk for heart attack and heart failure in the last two drugs. The FDA has removed Avandia from pharmacy shelves, and the agency issued a warning last summer that there is a possible increased risk of bladder cancer in patients who take Actos for more than a year.

The concerns about Januvia and Byetta "should not be blown out of proportion," Banerji said. "You prescribe them on an individual basis, because, in the end, all of medicine is individual," she said. "We should use these drugs judiciously along with metformin."

Industry representatives, insisting that no studies involving these drugs have found an increased risk of pancreatitis or pancreatic cancer, stand by their products. The database used for the study contains information on doctor-reported cases and does not reflect cause-and-effect, they said.

Dr. Barry Goldstein, vice president and therapeutic area head for diabetes and endocrinology at Merck Research Laboratories, which makes Januvia, said that "there has been no association shown between Januvia and pancreatitis."

"We have full confidence in Januvia, which is used by millions of patients around the world," he said.

Anne Erickson, a spokeswoman for Amylin Pharmaceuticals, makers of Byetta, said that "the conclusions of the study are in contrast to other nonclinical, clinical and adequately conducted post-marketing epidemiological studies."

Epidemiological studies have not established a significantly increased risk of pancreatitis associated with Byetta, she said. "To date, the available data do not demonstrate that exenatide increases the overall risk of cancer in humans."

Another expert, Dr. Ronald Goldberg, professor of medicine, biochemistry and molecular biology at the University of Miami Miller School of Medicine, said the findings merit consideration. "I don't think the study is definitive, but it raises a flag and is clearly something we need to pay attention to going forward."

There is "more benefit than risk with these drugs, based on our current knowledge," he

Vaginal Mesh Update, Vaginal Mesh Lawyers

Vaginal mesh lawsuits have been consolidated in three major jurisdictions: West Virginia, New Jersey and Georgia. There are a total of 6 MDL's that are currently active. No matter where your case is filed it will most likely end up in one of these under the auspices of a lead cousel that will proceed on your behalf. These are not class actions but, consolidations. This is very different as it is still on an individual settlemement basis. Just to give you a point of reference the first Yaz settlements have settled for $250,000 for the first grouo of victims and the DePuy for $600,000 for six victims.

Problems with vaginal mesh systems marketed by a number of different medical device manufacturers have caused thousands of women throughout the United States to suffer severe injuries. The major manufactures involved in the litgations are Johnson and Johnson, Bard, Boston Scientific, and American Medical. Johnson and Johnson has just recently pulled 4 of the Gynecare mesh off the market and has published  a new label change for one still on the market.

The vaginal mesh lawsuit lawyers are filing mesh lawsuits for women who have received any type of surgical mesh or bladder sling to repair pelvic organ prolapse, which could include:

    Bard Avaulta Support System
    AMS Elevate Prolapse Repair System
    AMS Apogee Vault Suspension System
    AMS Perigee System
    AMS Monarc Sling System
    AMS Sparc Sling System
    Ethicon Gynecare Gynemesh
    Ethicon Gynecare Prolene Soft Mesh
    Ethicon Gynecare Prolift Pelvic Floor Repair System
    Ethicon Gynecare TVT Transvaginal Sling
    Boston Scientific Pinnacle Pelvic Floor Repair Kit
    Boston Scientific Uphold Vaginal Support System
    UGYTEX Dual Knit Mesh
    Coviden IVS Tunneler Sling

Due to the risk of vaginal mesh complications, the FDA warned in July 2011 that doctors should recognize that in most cases, pelvic organ prolapse can be treated successfully without a bladder sling or pelvic mesh. Thousands of women had a bladder sling or vaginal mesh implanted in recent years, and compensation may be available for serious injuries caused by the defective and dangerous design of the pelvic support systems.

Mesh lawsuits should be filed quickly as the staute of limitations is running close in many states and some are past the filing date already.